Pharming Group N.V.
napazimone (KL1333)
primary mitochondrial disease
Countdown
542days
Phase 3 readout · ~ Dec 31, 2027 estimated
What's at stake
Phase 3 trial results for napazimone (KL1333) in primary mitochondrial disease are due ~ Dec 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“Advancing the clinical pipeline with key 2026 milestones including Phase II leniolisib readouts in PIDs with immune dysregulation and pivotal FALCON study enrollment completion for napazimone (KL1333) in primary mitochondrial disease”